March 1, 2019 05:01 AM EST
People

Ea­ger to think big­ger than Chi­na, As­cle­tis woos top Mer­ck ex­ec to run R&D

Amber Tong

Hav­ing paved the way in de­vel­op­ing and com­mer­cial­iz­ing Chi­na’s first home-cul­ti­vat­ed he­pati­tis C drug — with some help from a multi­na­tion­al phar­ma part­ner — As­cle­tis has now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

A service from the Financial Times